Statistics from Altmetric.com
We read the article on ‘Generic medications in ophthalmology’ by Zore et al1 with great interest. The authors comprehensively describe the regulations that ensure ‘equivalence’ of generic products with branded versions. One aspect of this in ophthalmology, which is overlooked, is the issue of medication compliance with generic eye drops. In order to gain an insight into this, in our own patient population, we conceived an audit looking at generic latanoprost.
Latanoprost was the first prostaglandin analogue to be licensed for the treatment of primary open angle glaucoma and ocular hypertension. In 2012, the patent to …